High intravitreal TGF-β1 and MMP-9 levels in eyes with retinal vein occlusion

被引:23
作者
Tuuminen, R. [1 ]
Loukovaara, S. [2 ]
机构
[1] Univ Helsinki, Cent Hosp, Dept Ophthalmol, FI-00290 Helsinki, Finland
[2] Univ Helsinki, Cent Hosp, Dept Ophthalmol, Unit Vitreoretinal Surg, FI-00290 Helsinki, Finland
关键词
PROLIFERATIVE VITREORETINAL DISEASES; TO-MESENCHYMAL TRANSITION; GROWTH-FACTOR; MATRIX METALLOPROTEINASES; DIABETIC-RETINOPATHY; OXYGEN-SATURATION; MACULAR EDEMA; RISK-FACTORS; TGF-BETA; ERYTHROPOIETIN;
D O I
10.1038/eye.2014.137
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose Vascular endothelial growth factor is a leading target to reduce macular oedema and improve visual acuity in patients with retinal vein occlusion (RVO), whereas the role of vascular destabilizing and fibroproliferative transforming growth factor (TGF)-beta 1 and matrix metalloproteinases (MMP)-2 and -9 in pathological manifestations of RVO is anticipated but less studied. Methods Undiluted vitreous samples were collected from three central RVO and one branch RVO eyes, all with neovascularization and fibrosis-related sight-threatening complications of RVO. Undiluted vitreous samples of 40 eyes operated due to non-ischemic condition either macular hole or pucker were used as controls. Growth factor and protease concentrations were measured by ELISA and gelatin zymography. Results Vitreous concentrations of TGF-beta 1 (92.0 +/- 17.4 pg/ml vs 18.3 +/- 27.0 pg/ml, mean +/- SD; P = 0.002) and MMP-9 (847.9 +/- 1196.4 AU/ml vs 87.7 +/- 174.0 AU/ml; P = 0.010) were higher in the eyes with ischemic RVO than in the controls. Conclusions High intravitreal levels of TGF-beta 1 and MMP-9 are found in RVO eyes having neovascular and fibrosis manifestation. Further studies are warranted to elucidate whether targeting TGF-beta 1 and MMP-9 could be beneficial in patients with ischemic RVO.
引用
收藏
页码:1095 / 1099
页数:5
相关论文
共 37 条
[1]  
Behzadian MA, 2001, INVEST OPHTH VIS SCI, V42, P853
[2]  
Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
[3]   Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study [J].
Campochiaro, Peter A. ;
Heier, Jeffrey S. ;
Feiner, Leonard ;
Gray, Sarah ;
Saroj, Namrata ;
Rundle, Amy Chen ;
Murahashi, Wendy Yee ;
Rubio, Roman G. .
OPHTHALMOLOGY, 2010, 117 (06) :1102-U111
[4]   From oxygen to erythropoietin: Relevance of hypoxia for retinal development, health and disease [J].
Caprara, Christian ;
Grimm, Christian .
PROGRESS IN RETINAL AND EYE RESEARCH, 2012, 31 (01) :89-119
[5]   CORRELATION OF FIBROSIS AND TRANSFORMING GROWTH FACTOR-BETA TYPE-2 LEVELS IN THE EYE [J].
CONNOR, TB ;
ROBERTS, AB ;
SPORN, MB ;
DANIELPOUR, D ;
DART, LL ;
MICHELS, RG ;
DEBUSTROS, S ;
ENGER, C ;
KATO, H ;
LANSING, M ;
HAYASHI, H ;
GLASER, BM .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (05) :1661-1666
[6]  
Das A, 1999, ARCH OPHTHALMOL-CHIC, V117, P498
[7]  
De la Paz MA, 1998, INVEST OPHTH VIS SCI, V39, P1256
[8]  
ELMAN MJ, 1990, OPHTHALMOLOGY, V97, P1543
[9]   Benefit from Bevacizumab for Macular Edema in Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized Study [J].
Epstein, David L. ;
Algvere, Peep V. ;
von Wendt, Gunvor ;
Seregard, Stefan ;
Kvanta, Anders .
OPHTHALMOLOGY, 2012, 119 (12) :2587-2591
[10]   Decreased Hypoxia-Induced Neovascularization in Angiopoietin-2 Heterozygous Knockout Mouse through Reduced MMP Activity [J].
Feng, Yuxi ;
Wang, Yumei ;
Pfister, Frederick ;
Hillebrands, Jan-Luuk ;
Deutsch, Urban ;
Hammes, Hans-Peter .
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2009, 23 (4-6) :277-284